AdvaMed Statement on Biden’s Cancer Moonshot Commitment
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed), the largest trade association representing medical device manufacturers, including all major radiation therapy manufacturers in the U.S. and abroad. released the following statement from President and CEO Scott Whitaker in response to President Biden’s Cancer Moonshot commitment in the annual State of the Union Address.
“The medtech industry is at the forefront of cancer diagnosis and treatment, developing innovative technologies and diagnostic tests that are transforming health care,” said Scott Whitaker, AdvaMed President and CEO. “AdvaMed shares President Biden’s goal of ending cancer as we know it, and we can achieve that by making greater investments and research into proven cancer treatments such as radiation therapy and diagnostics that detect cancer early when treatment is most effective. We stand ready to lend our expertise and support to this endeavor in the coming years, and we thank the President for his commitment to expanding access to life-saving medical technologies for cancer patients.”
Last year, AdvaMed encouraged the Biden Administration to make use of medtech industry leaders and their deep experience in the detection, diagnosis, and treatment of cancer as part of the Cancer Moonshot. The Association also applauded the White House for progress that has been made on the Cancer Moonshot, including appointing members to the Cancer Cabinet and unveiling priority actions.
###
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.